Clinical Trial Update: A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Eciskafusp Alfa in combination with Bacillus Calmette-Guérin for BCG-unresponsive high-risk Non-muscle Invasive Bladder Cancer has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (Bacillus Calmette-Guérin)
• Eciskafusp Alfa (eciskafusp alfa)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-muscle Invasive Bladder Cancer | Phase 1 | Status: WITHDRAWN